Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LIM domain binding protein 3 (LDB3), also known as Z-band alternatively spliced PDZ-motif protein (ZASP) or Cypher, is a cytoskeletal scaffolding protein strongly expressed in both cardiac and skeletal muscle[1][7][3][5]. It contains a PDZ domain at the N-terminal, allowing it to bind to α-actinin and other proteins involved in sarcomere assembly, and one or more C-terminal LIM domains (depending on the isoform), which mediate interactions with signaling molecules such as protein kinase C[1][5][7]. LDB3's primary biological role is to stabilize and maintain the structure of the Z-disc within muscle sarcomeres and to act as an adapter that integrates structural and signaling cues during muscle contraction and mechanical stress[1][5][3]. Mutations in LDB3 are causatively linked to several muscle diseases, notably dilated cardiomyopathy, left ventricular noncompaction, and myofibrillar myopathy[3][1][7]. There are no established direct drugs—which is typical for a structural cytoskeletal protein—but its mutation status is emerging as a genetic biomarker for patient stratification in hereditary cardiomyopathies[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LIM domain binding protein 3 (LDB3).